Comparison of short- and long-term treatment protocols and the results of second-line quadruple therapy in children with Helicobacter pylori infection

被引:23
|
作者
Usta, Yusuf [1 ]
Saltik-Temizel, Inci Nur [1 ]
Demir, Hulya [1 ]
Uslu, Nuray [1 ]
Ozen, Hasan [1 ]
Gurakan, Figen [1 ]
Yuce, Aysel [1 ]
机构
[1] Hacettepe Univ, Sch Med, Dept Pediat, Div Gastroenterol Hepatol & Nutr, TR-06100 Ankara, Turkey
关键词
Helicobacter pylori; triple therapy; quadruple therapy; eradication rate; children;
D O I
10.1007/s00535-008-2187-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Research regarding the optimal therapeutic approach to Helicobacter pylori infection in children is ongoing. There is no consensus as to duration of treatment or second-line therapy. The purpose of this study was compare the efficacy of 7-day and 14-day triple therapies and report the results of second-line quadruple therapy in children. Methods. A total of 275 consecutive H. pylori-infected patients were enrolled into two groups. Group 1 (n = 180) received triple therapy with 14 days of amoxicillin and clarithromycin and 21 days of proton pump inhibitor. Group 2 (n = 95) received triple therapy including 7 days of amoxicillin and clarithromycin with 21 days of proton pump inhibitor. Subsequently, 89 patients not responding to the triple therapies received quadruple therapy comprising omeprazole (14 days), bismuth subcitrate (7 days), doxycycline (7 days), and metronidazole (7 days). Eradication was evaluated by 13 C-urea breath test. Results. The per-protocol eradication rates in groups I and 2 were 60.5 % and 55.8 %, respectively (P = 0.44). In the second interview with 227 patients, severe symptoms were reported to have disappeared in 59% and decreased notably in 34.8%. Helicobacter pylori was eradicated in 66.7% of patients at the end of the quadruple therapy. In the third interview with 75 patients, severe symptoms had decreased in 38.6% and disappeared in 56%. Conclusions. The different duration of the two treatment regimens had no impact on eradication rates. Furthermore, quadruple therapy was necessary to achieve H. pylori eradication after triple therapy. However, the eradication rate with quadruple therapy was still insufficient. Consequently, a new therapeutic approach to H. pylori infection in children is needed.
引用
收藏
页码:429 / 433
页数:5
相关论文
共 50 条
  • [41] Eradication rate of Bismuth-containing quadruple therapy as a second-line treatment for H-pylori infection
    Jee, S. R.
    Lee, S. H.
    Jung, E. U.
    Ok, K. S.
    Kim, J. H.
    Choi, J. S.
    Lee, Y. J.
    Seol, S. Y.
    HELICOBACTER, 2010, 15 (04) : 345 - 345
  • [42] Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
    Lin, Te-Fu
    Hsu, Ping-I
    WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (40) : 4548 - 4553
  • [43] Moxifloxacin-Containing Triple Therapy versus Bismuth-Containing Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis
    Wu, Cheng
    Chen, Xiao
    Liu, Jing
    Li, Ming-Yang
    Zhang, Zi-Qi
    Wang, Zhi-Qiang
    HELICOBACTER, 2011, 16 (02) : 131 - 138
  • [44] Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial
    Bago, Josip
    Pevec, Branko
    Tomic, Monika
    Marusic, Marinko
    Bakula, Vinko
    Bago, Petra
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (1-2) : 47 - 52
  • [45] Second-line treatment for Helicobacter pylori infection:: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy
    Kang, Jung Mook
    Kim, Nayoung
    Lee, Dong Ho
    Park, Young Soo
    Kim, Yu Rim
    Kim, Joo Sung
    Jung, Hyun Chae
    Song, In Sung
    HELICOBACTER, 2007, 12 (06) : 623 - 628
  • [46] Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection
    José M Navarro-Jarabo
    Nuria Fernández
    Francisca L Sousa
    Encarnación Cabrera
    Manuel Castro
    Luz M Ramírez
    Robin Rivera
    Esther Ubiña
    Francisco Vera
    Isabel Méndez
    Francisco Rivas-Ruiz
    José L Moreno
    Emilio Perea-Milla
    BMC Gastroenterology, 7
  • [47] Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection
    Navarro-Jarabo, Jose M.
    Fernandez, Nuria
    Sousa, Francisca L.
    Cabrera, Encarnacion
    Castro, Manuel
    Ramirez, Luz M.
    Rivera, Robin
    Ubina, Esther
    Vera, Francisco
    Mendez, Isabel
    Rivas-Ruiz, Francisco
    Moreno, Jose L.
    Perea-Milla, Emilio
    BMC GASTROENTEROLOGY, 2007, 7 (1)
  • [48] Trend of First-Line and Second-Line Eradication Therapy for Helicobacter pylori Infection in Korea
    Chung, Jun-Won
    Jung, Hwoon-Yong
    Choi, Kee Don
    Song, Ho June
    Choi, Kwi-Sook
    Jung, Kee Wook
    Lee, Gin Hyug
    Kim, Do Hoon
    Kim, Jin-Ho
    GASTROENTEROLOGY, 2009, 136 (05) : A24 - A24
  • [49] Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line
    Simona Di Caro
    Lucia Fini
    Yayha Daoud
    Fabio Grizzi
    Antonio Gasbarrini
    Antonino De Lorenzo
    Laura Di Renzo
    Sara McCartney
    Stuart Bloom
    World Journal of Gastroenterology, 2012, 18 (40) : 5669 - 5678
  • [50] Helicobacter pylori Eradication Rates and Related Factors by Second-Line Bismuth-Based Quadruple Therapy
    Kim, Sung Eun
    Park, Moo In
    Park, Seun Ja
    Moon, Won
    Lee, Jun Yeob
    Lee, Jin Wook
    Kim, Hae Koo
    Nam, Kyoung Sik
    Nam, Yong Jin
    GASTROENTEROLOGY, 2016, 150 (04) : S881 - S881